Hey everyone, Just wanted to share an important message that Jeff Cohen put out from their firm's TikTok account this morning. For those who don't know, Jeff represents some major companies in the peptide space, so when he speaks, it's worth paying attention. Please watch the full video - I don't like to put words in anyone's mouth, and the full context matters here. From what I'm seeing, my assumptions seem to be correct that something bigger is coming. This isn't just about FDA 66-80 or the SAFE Drug Act - there appears to be something specifically targeting the research space as well. I know regulatory uncertainty is stressful for all of us, but staying informed is our best defense. As always, I will keep everyone in the loop as I learn more. Drop your thoughts below after watching 👇

My DMs have been flooded all week. "Derek, is this the end?" "Are prices going up?" "Should I stock up?" So I broke it all down: → What 66-80 actually does → How it hits compounding pharmacies (spoiler: it's real) → Why ALL research peptides might see price increases (not just GLP-1s) → The liquidation sales happening right now—and why I don't think 66-80 is the reason → What I'm actually watching over the next few months Short version: I've yet to see anything kill this space. I don't see it happening as fast as everyone's panicking about. But there ARE real implications here. Full breakdown 👇 https://open.substack.com/pub/derekpruski/p/fda-import-alert-66-80-what-it-actually?r=4jq1x8&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

I wanted to solicit feedback from people who have an RS who DID NOT have success with Reta. I know you are out there and silent because Reta is so universally loved. Maybe your RS did better with Tirz. Maybe your RS had bad side effects and stopped? Maybe your RS got no results at all. Give me your stories please! I have a theory that I am trying to either validate or disprove. My theory is that Reta works really well for a certain type of RS, but not for everyone.

Quick reminder about all this fear mongering is going on with the GLP ones. Established the healthy lifestyle habits, and it’ll make your journey a lot easier. Whether it’s going on a walk with your family hitting the gym or playing a sport get out there and get active.

2 Congressman from Indiana (home of Eli Lilly) sponsored legislation to place strong limits on access to compounded GLP-1 medications. Sign the petition to express your desire to keep compounding pharmacies free from regulations restricting access to peptides. https://c.org/4gv8qKVNKN The federal SAFE Drugs Act refers to a piece of proposed U.S. legislation introduced in Congress in December 2025 known as the “Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025.” It is not yet law, but it represents a legislative effort focused on tightening the safety and oversight of certain drug practices. Here’s the essence of what it’s about: This bill, introduced by Representatives Rudy Yakym and André Carson, aims to protect patients from unsafe compounded medications. Compound drugs are those created by pharmacies to meet the specific needs of individual patients — say a liquid form for someone who can’t swallow pills — but some compounded products have been mass-produced and distributed in ways that bypass the standard Food and Drug Administration (FDA) approval process. According to the sponsors and supporters, that can expose patients to untested and potentially hazardous medications. The SAFE Drugs Act would likely: - Increase FDA oversight and reporting requirements for compounded drugs so that regulators have better visibility into what is being made and where it’s going. - Raise safety standards to reduce the likelihood that unapproved or unsafe compounded medications reach patients. - Restore transparency and accountability in that segment of the drug supply chain that has grown rapidly without uniform federal controls. In simple terms, the bill’s core goal is to make sure that when a drug is created outside the usual FDA approval pathways — especially at scale — there are stronger safeguards so Americans aren’t exposed to fraudulent or experimental medications without proper testing and oversight.